ArticleJournal of the American College of Emergency Physicians open2025
Real-World Study Assessing Sensitivity and Clinical Utility of a Host-Protein Test in Adult Emergency Department Patients With Blood Culture Ordered.
Article in Journal of the American College of Emergency Physicians open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Constructive Appraisal of "Real-World Study Assessing Sensitivity and Clinical Utility of a Host-Protein Test in Adult Emergency Department Patients With Blood Culture Ordered".Journal of the American College of Emergency Physicians open · 2026Article
- Clinical utility of a host-protein test for suspected infection in the pediatric emergency department: a pragmatic pre-/post-implementation study.Frontiers in pediatrics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Difficulty in distinguishing bacterial from viral infections leads to suboptimal patient management. MeMed BV (MMBV) is a Food and Drug Administration-cleared host-protein test with >98% negative predictive value (NPV) for distinguishing bacterial (including coinfection) from viral infections. This study aimed to validate MMBV's sensitivity compared with blood cultures and assess clinical impact over time. Methods: At Maimonides Medical Center emergency department (ED) (March 2022 to March 2024), adults were included if both MMBV and blood cultures were ordered at the physician's discretion. Sensitivity was evaluated against clinically relevant blood cultures. Alignment was defined as not prescribing antibiotics for MMBV viral results (score <35) and prescribing for bacterial (score >65). Outcomes included prescribing alignment, antibiotic prescription, hospital admission, and 7-day ED-return visits. Outcomes were compared across matching time periods: April 2022 to March 2023 (period 1) and April 2023 to March 2024 (period 2). Results: The study included 681 adults (median age, 72 years; 52.9% male), with 58 clinically relevant blood cultures, 29 contaminated cultures, and 594 negative cultures. MMBV attained 96.4% sensitivity (95% CI, 87.0-99.7) and 98.6% NPV (94.5-99.9). Comparing period 1 (n = 353) with period 2 (n = 291), antibiotic prescription among patients with viral MMBV results decreased from 80.7% to 61.4% ( Conclusion: MMBV demonstrated high sensitivity. Increased test alignment is associated with reduced antibiotic prescription and hospital admission in viral MMBV cases without compromising safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.